NCT00956553已完成4 期
A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 4
- 主要终点
- Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45
研究概览
简要总结
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
详细描述
This study looks at possible cross reactivity between different HPV serotypes and both peripheral antibodies and mucosally-secreted antibodies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 13 Years 至 15 Years（Child）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Aged between 13 and 15 years at the time of the first immunisation
- •No contraindications to vaccination as specified in the "Green Book" - Immunisation Against Infectious Disease, HMSO.
- •Written informed consent obtained from parent or guardian of subject
排除标准
- •Pregnant or become pregnant during the course of the trial (no contraindications to vaccination for those taking the contraceptive pill).
- •Breast-feeding mothers
- •Allergic to vaccine components
结局指标
主要结局
Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45
时间窗: 18 months from enrollment
次要结局
- Determine differences in vaccine formulation and their impact on cross protection.(24 months from enrollment)
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
4 期
Phase IV Study of Concomitant Administration of the sIPV and HepAPolioHepatitis ANCT06460545Institute of Medical Biology, Chinese Academy of Medical Sciences2,000
已完成
4 期
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 YearsHerpes ZosterNCT04869982GlaxoSmithKline6,138
进行中（未招募）
1 期
A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines - RCT of immune response in UK adolescent girls to HPV vaccinesThis study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.MedDRA version: 9.1 Level: LLT Classification code 10058580 Term: Human papilloma virus serology testEUCTR2008-006773-32-GBHealth Protection Agency84
进行中（未招募）
不适用
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against:Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), Haemophilus influenza ttype b (Hib disease)Menjugate and Nies-VacC - meningococcal C diseasePrevenar - pneumococcal diseaseMedDRA version: 9.1Level: PTClassification code 10027274Term: Meningococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10013023Term: DiphtheriaMedDRA version: 9.1Level: LLTClassification code 10043376Term: TetanusMedDRA version: 9.1Level: LLTClassification code 10034738Term: PertussisMedDRA version: 9.1Level: LLTClassification code 10018955Term: Haemophilus meningitisMedDRA version: 9.1Level: LLTClassification code 10036008Term: PolioEUCTR2007-004056-36-GBHealth Protection Agency
已完成
4 期
Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A VaccinesHepatitis ANCT02601040Jiangsu Province Centers for Disease Control and Prevention13,500